BNF for Children 2011-2012

More documents

Recommendations

Info

802 Index of manufacturers BNFC 2011–2012Index of manufacturersCliniMedCliniMed Ltdtel: (01628) 535 250enquires@clinimed.co.ukClinisuppliesClinisupplies Ltdtel: (020) 8863 4168info@clinisupplies.co.ukColgate-PalmoliveColgate-Palmolive Ltdtel: (01483) 302 222ColoplastColoplast Ltdtel: (01733) 392 000gbcareteam@coloplast.comCommunityCommunity Foods Ltdtel: (020) 8450 9411email@communityfoods.co.ukComplan FoodsComplan Foods Ltdtel: (020) 7395 7565ConsilientConsilient Health UK Ltdtel: (020) 8956 2310drugsafety@consilienthealth.comConvaTecConvaTec Ltdtel: (01895) 628 400Co-PharmaCo-Pharma Ltdtel: 0870 851 0207co-pharma@medinformation.co.ukCovidienCovidien UK Commercial Ltdtel: (01329) 224 226medicalcustomerservices@covidien.comCow & GateCow & Gatetel: 0845 762 3624careline@inpractice.co.ukCranageCranage Healthcare Ltdtel: (01477) 549 392db@cranagehealth.comCrawfordCrawford Healthcare Ltdtel: (01565) 654 920CrucellCrucell (UK) Ltdtel: 0844 800 3908info@crucell.co.ukCSL BehringCSL Behring UK Ltdtel: (01444) 447 400medinfo@cslbehring.comDaiichi SankyoDaiichi Sankyo UK Ltdtel: (01753) 482 771medinfo@daiichi-sankyo.co.ukDanetreDanetre Health Products Ltdtel: (01327) 310 909enquiries@danetrehealthproducts.comDDDDDD Ltdtel: (01923) 229 251DeeDee Pharmaceuticals Ltdtel: (01978) 661993enquiries@deepharmaceuticalsltd.co.ukDental HealthDental Health Products Ltdtel: (01622) 749 222DentsplyDentsply Ltdtel: (01932) 837 279DermalDermal Laboratories Ltdtel: (01462) 458 866DermatonicsDermatonics Ltdtel: (01480) 462 910sales@dermatonics.co.ukDerma UKDerma UK Ltdtel: (01462) 733 500info@dermauk.co.ukDeVilbissDeVilbiss Healthcare UK Ltdtel: (01384) 446 688DexcelDexcel-Pharma Ltdtel: (01327) 312 266office@dexcelpharma.co.ukDHP HealthcareDHP Healthcare Ltdtel: (01622) 749 222sales@dhphealthcare.co.ukDreamskinDreamskin Health Ltdtel: (01727) 668 288medinfo@dreamskinhealth.co.ukDr FalkDr Falk Pharma UK Ltdtel: (01628) 536 600DrossaDrossa Ltdtel: (020) 3393 0859info@drossa.co.ukDurbinDurbin plctel: (020) 8869 6500info@durbin.co.ukEakinT G Eakintel: (028) 9187 1000mail@eakin.co.ukEasigripEasigrip Ltdtel: (01926) 497 108enquiry@easigrip.co.ukEcolabEcolab UKtel: (0113) 232 0066info.healthcare@ecolab.co.ukEgisEgis Pharmaceuticals UK Ltdtel: (020) 7266 2669enquiries@medimpexuk.comEisaiEisai Ltdtel: (020) 8600 1400lmedinfo@eisai.netEncysiveEncysive (UK) Ltdtel: (01895) 876 168enquiries@encysive.co.ukEspereEspere Healthcare Ltdtel: (01234) 834 614info@esperehealth.co.ukEthiconEthicon Ltdtel: (01506) 594 500EumedicaEumedica S.A.tel: (020) 8444 3377enquiries@eumedica.comEUSA PharmaEUSA Pharma (Europe) Ltdtel: (01438) 740 720medinfo-uk@eusapharma.comEverfreshEverfresh Natural Foodstel: (01296) 425 333FabrePierre Fabre Ltdtel: (01962) 874 435medicalinformation@pierre-fabre.co.ukFateFate Special Foodstel: (01215) 224 433
BNFC 2011–2012 Index of manufacturers 803FentonFenton Pharmaceuticals Ltdtel: (020) 7224 1388mail@Fent-Pharm.co.ukFerndaleFerndale Pharmaceuticals Ltdtel: (01937) 541 122info@ferndalepharma.co.ukFerringFerring Pharmaceuticals (UK)tel: 0844 931 0054medical@ferring.comFirstplay DietaryFirstplay Dietary Foods Ltdtel: (0161) 474 7576FlynnFlynn Pharma Ltdtel: (01438) 727 822medinfo@flynnpharma.comFoodlinkFoodlink (UK) Ltdtel: (01752) 344 544info@foodlinkltd.co.ukFordFord Medical Associates Ltdtel: (01233) 633 224enquiries@fordmedical.co.ukForestForest Laboratories UK Ltdtel: (01322) 421 800medinfo@forest-labs.co.ukForumForum Health Products Ltdtel: (01737) 773 711health@forumgroup.co.ukFoxC. H. Fox Ltdtel: (020) 7240 3111Fresenius KabiFresenius Kabi Ltdtel: (01928) 533 533med.info-uk@fresenius-kabi.comFresenius Medical CareFresenius Medical Care UK Ltdtel: (01623) 445 139medinfo-uk@fmc-ag.comFrontierFrontier Multigatetel: (01495) 233 050multigate@frontier-group.co.ukFyne DynamicsFyne Dynamics Ltdtel: (01279) 423 423info@fyne-dynamics.comGaldermaGalderma (UK) Ltdtel: (01923) 208 950GalenGalen Ltdtel: (028) 3833 4974customer.services@galen.co.ukGE HealthcareGE Healthcaretel: (01494) 544 000GeistlichGeistlich Pharmatel: (01244) 347 534General DietaryGeneral Dietary Ltdtel: (020) 8336 2323GenericsSee MylanGenius FoodsGenius Foods Ltdtel: 0845 874 4000info@geniusglutenfree.comGenopharmLaboratoires Genopharmtel: (0808) 234 2664info@genopharm.euGenusGenus Pharmaceuticalstel: (01635) 568 400info@genuspharma.comGenzymeGenzyme Therapeuticstel: (01865) 405 200ukmedinfo@genzyme.comGFF TradeGF Foods Ltdtel: (01757) 289 207admin@gffdirect.co.ukGileadGilead Sciences Ltdtel: (01223) 897 555ukmedinfo@gilead.comGlebe FarmGlebe Farmtel: (01487) 773 282office@glebe-flour.co.ukGlenwoodGlenwood GmbHtel: (0049) 815 199 8790info@glenwood.deGluten Free Foods LtdGluten Free Foods Ltdtel: (020) 8953 4444info@glutenfree-foods.co.ukGoldshieldGoldshield Pharmaceuticals Ltdtel: 0870 070 3033medicalinformation@goldshieldplc.comGP PharmaSee Derma UKGrifolsGrifols UK Ltdtel: (01223) 395 700reception.uk@grifols.comGrünenthalGrünenthal Ltdtel: 0870 351 8960medicalinformationuk@grunenthal.comGSKGlaxoSmithKlinetel: 0800 221 441customercontactuk@gsk.comGSK Consumer HealthcareGlaxoSmithKline Consumer Healthcaretel: (020) 8047 2500customer.relations@gsk.comH&RH&R Healthcare Ltdtel: (01482) 638 491HamptonHampton Pharmaceuticals Ltdtel: (01923) 251 777HartmannPaul Hartmann Ltdtel: (01706) 363 200info@uk.hartmann.infoHeinzH. J. Heinz Company Ltdtel: (020) 8573 7757farleys_heinz@heinz.co.ukHenleysHenleys Medical Supplies Ltdtel: (01707) 333 164HFA HealthcareHFA Healthcare Ltdtel: 0844 335 8270HK PharmaHK Pharma Ltdtel: (01438) 356 926HollisterHollister Ltdtel: (0118) 989 5000customer.services@hollister.comHospiraHospira UK Ltdtel: (01926) 834 400medinfouk@hospira.comHRA PharmaHRA Pharma UK Ltdtel: 0800 917 9548med.info.uk@hra-pharma.comHuntleighHuntleigh Healthcare Ltdtel: (01582) 413 104IdisIdis Ltdtel: (01932) 824 000mi@idispharma.comIndex of manufacturers
Page 2 and 3:
Medicines information servicesInfor
Page 4 and 5:
Published byBMJ GroupTavistock Squa
Page 6 and 7:
iv BNFC 2011-2012PrefaceBNF for Chi
Page 8 and 9:
vi BNFC 2011-2012BNF StaffDigital D
Page 10 and 11:
viii BNFC 2011-2012Nurse Prescriber
Page 12 and 13:
x BNFC 2011-2012. incorporating the
Page 14 and 15:
xii BNFC 2011-2012prescribing notes
Page 16 and 17:
Branded oral liquid preparations th
Page 18 and 19:
xvi BNFC 2011-2012Finding significa
Page 20 and 21:
xviii BNFC 2011-2012Epilim Chronosp
Page 22 and 23:
xx BNFC 2011-2012Tears Naturale c S
Page 24 and 25:
2 General guidance BNFC 2011-2012Ge
Page 26 and 27:
4 Prescription writing BNFC 2011-20
Page 28 and 29:
6 Supply of medicines BNFC 2011-201
Page 30 and 31:
8 Emergency supply of medicines BNF
Page 32 and 33:
10 Prescribing Controlled Drugs BNF
Page 34 and 35:
Adverse reactions to drugs12 Advers
Page 36 and 37:
Prescribing in hepatic impairment14
Page 38 and 39:
Prescribing in pregnancy16 Prescrib
Page 40 and 41:
18 Prescribing in palliative care B
Page 42 and 43:
20 Prescribing in palliative care B
Page 44 and 45:
22 Prescribing in dental practice B
Page 46 and 47:
Emergency treatment of poisoning24
Page 48 and 49:
26 Emergency treatment of poisoning
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
36 1.1.1 Antacids and simeticone BN
Page 60 and 61:
38 1.1.2 Compound alginate preparat
Page 62 and 63:
40 1.2 Antispasmodics and other dru
Page 64 and 65:
42 1.3 Antisecretory drugs and muco
Page 66 and 67:
44 1.3.3 Chelates and complexes BNF
Page 68 and 69:
46 1.4 Acute diarrhoea BNFC 2011-20
Page 70 and 71:
48 1.5 Chronic bowel disorders BNFC
Page 72 and 73:
50 1.5.1 Aminosalicylates BNFC 2011
Page 74 and 75:
52 1.5.1 Aminosalicylates BNFC 2011
Page 76 and 77:
54 1.5.3 Drugs affecting the immune
Page 78 and 79:
56 1.5.4 Food allergy BNFC 2011-201
Page 80 and 81:
58 1.6.1 Bulk-forming laxatives BNF
Page 82 and 83:
60 1.6.2 Stimulant laxatives BNFC 2
Page 84 and 85:
62 1.6.4 Osmotic laxatives BNFC 201
Page 86 and 87:
64 1.6.5 Bowel cleansing preparatio
Page 88 and 89:
66 1.7 Local preparations for anal
Page 90 and 91:
68 1.8 Stoma and enteral feeding tu
Page 92 and 93:
70 1.9.2 Bile acid sequestrants BNF
Page 94 and 95:
72 1.9.4 Pancreatin BNFC 2011-20121
Page 96 and 97:
74 2.1.1 Cardiac glycosides BNFC 20
Page 98 and 99:
76 2.2 Diuretics BNFC 2011-20122 Ca
Page 100 and 101:
78 2.2.2 Loop diuretics BNFC 2011-2
Page 103 and 104:
BNFC 2011-2012 2.2.4 Potassium-spar
Page 105 and 106:
BNFC 2011-2012 2.3.2 Drugs for arrh
Page 107 and 108:
BNFC 2011-2012 2.3.2 Drugs for arrh
Page 109 and 110:
BNFC 2011-2012 2.4 Beta-adrenocepto
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
BNFC 2011-2012 2.5.1 Vasodilator an
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
BNFC 2011-2012 2.5.4 Alpha-adrenoce
Page 123 and 124:
BNFC 2011-2012 2.5.5 Drugs affectin
Page 125 and 126:
BNFC 2011-2012 2.5.5 Drugs affectin
Page 127 and 128:
BNFC 2011-2012 2.6.2 Calcium-channe
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
BNFC 2011-2012 2.7.1 Inotropic symp
Page 135 and 136:
BNFC 2011-2012 2.7.2 Vasoconstricto
Page 137 and 138:
BNFC 2011-2012 2.8.1 Parenteral ant
Page 139 and 140:
BNFC 2011-2012 2.8.1 Parenteral ant
Page 141 and 142:
BNFC 2011-2012 2.8.2 Oral anticoagu
Page 143 and 144:
BNFC 2011-2012 2.10 Myocardial infa
Page 145 and 146:
BNFC 2011-2012 2.11 Antifibrinolyti
Page 147 and 148:
BNFC 2011-2012 2.12 Lipid-regulatin
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
BNFC 2011-2012 2.14 Drugs affecting
Page 155 and 156:
BNFC 2011-2012 1333 Respiratory sys
Page 157 and 158:
BNFC 2011-2012 3.1 Bronchodilators
Page 159 and 160:
BNFC 2011-2012 3.1.1 Adrenoceptor a
Page 161 and 162:
BNFC 2011-2012 3.1.1 Adrenoceptor a
Page 163 and 164:
BNFC 2011-2012 3.1.2 Antimuscarinic
Page 165 and 166:
BNFC 2011-2012 3.1.3 Theophylline 1
Page 167 and 168:
BNFC 2011-2012 3.1.5 Peak flow mete
Page 169 and 170:
BNFC 2011-2012 3.2 Corticosteroids
Page 171 and 172:
Page 173 and 174:
BNFC 2011-2012 3.3 Cromoglicate and
Page 175 and 176:
BNFC 2011-2012 3.4 Antihistamines,
Page 177 and 178:
BNFC 2011-2012 3.4.1 Antihistamines
Page 179 and 180:
BNFC 2011-2012 3.4.2 Allergen immun
Page 181 and 182:
BNFC 2011-2012 3.4.3 Allergic emerg
Page 183 and 184:
BNFC 2011-2012 3.4.3 Allergic emerg
Page 185 and 186:
BNFC 2011-2012 3.6 Oxygen 163ment
Page 187 and 188:
BNFC 2011-2012 3.7 Mucolytics 165HO
Page 189 and 190:
BNFC 2011-2012 3.9 Cough preparatio
Page 191 and 192:
BNFC 2011-2012 1694 Central nervous
Page 193 and 194:
BNFC 2011-2012 4.1.2 Anxiolytics 17
Page 195 and 196:
BNFC 2011-2012 4.2.1 Antipsychotic
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
BNFC 2011-2012 4.3 Antidepressant d
Page 207 and 208:
BNFC 2011-2012 4.3.1 Tricyclic anti
Page 209 and 210:
BNFC 2011-2012 4.3.3 Selective sero
Page 211 and 212:
BNFC 2011-2012 4.4 CNS stimulants a
Page 213 and 214:
BNFC 2011-2012 4.5 Drugs used in th
Page 215 and 216:
BNFC 2011-2012 4.6 Drugs used in na
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
BNFC 2011-2012 4.7 Analgesics 199Sc
Page 223 and 224:
BNFC 2011-2012 4.7.1 Non-opioid ana
Page 225 and 226:
BNFC 2011-2012 4.7.2 Opioid analges
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
BNFC 2011-2012 4.7.4 Antimigraine d
Page 237 and 238:
BNFC 2011-2012 4.8 Antiepileptics 2
Page 239 and 240:
BNFC 2011-2012 4.8.1 Control of the
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
BNFC 2011-2012 4.8.2 Drugs used in
Page 255 and 256:
Page 257 and 258:
BNFC 2011-2012 4.8.3 Febrile convul
Page 259 and 260:
BNFC 2011-2012 4.9.2 Antimuscarinic
Page 261 and 262:
BNFC 2011-2012 4.10.2 Nicotine depe
Page 263 and 264:
BNFC 2011-2012 4.10.2 Nicotine depe
Page 265 and 266:
BNFC 2011-2012 5.1 Antibacterial dr
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
BNFC 2011-2012 5.1.1 Penicillins 25
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
BNFC 2011-2012 5.1.2 Cephalosporins
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
BNFC 2011-2012 5.1.3 Tetracyclines
Page 299 and 300:
BNFC 2011-2012 5.1.4 Aminoglycoside
Page 301 and 302:
BNFC 2011-2012 5.1.4 Aminoglycoside
Page 303 and 304:
BNFC 2011-2012 5.1.5 Macrolides 281
Page 305 and 306:
BNFC 2011-2012 5.1.6 Clindamycin 28
Page 307 and 308:
BNFC 2011-2012 5.1.7 Some other ant
Page 309 and 310:
BNFC 2011-2012 5.1.7 Some other ant
Page 311 and 312:
BNFC 2011-2012 5.1.8 Sulfonamides a
Page 313 and 314:
BNFC 2011-2012 5.1.9 Antituberculos
Page 315 and 316:
BNFC 2011-2012 5.1.9 Antituberculos
Page 317 and 318:
BNFC 2011-2012 5.1.11 Metronidazole
Page 319 and 320:
BNFC 2011-2012 5.1.12 Quinolones 29
Page 321 and 322:
BNFC 2011-2012 5.1.13 Urinary-tract
Page 323 and 324:
BNFC 2011-2012 5.2.1 Triazole antif
Page 325 and 326:
BNFC 2011-2012 5.2.1 Triazole antif
Page 327 and 328:
BNFC 2011-2012 5.2.2 Imidazole anti
Page 329 and 330:
BNFC 2011-2012 5.2.4 Echinocandin a
Page 331 and 332:
BNFC 2011-2012 5.3 Antiviral drugs
Page 333 and 334:
BNFC 2011-2012 5.3.1 HIV infection
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
BNFC 2011-2012 5.3.2 Herpesvirus in
Page 345 and 346:
BNFC 2011-2012 5.3.2 Herpesvirus in
Page 347 and 348:
BNFC 2011-2012 5.3.3 Viral hepatiti
Page 349 and 350:
BNFC 2011-2012 5.3.5 Respiratory sy
Page 351 and 352:
BNFC 2011-2012 5.4 Antiprotozoal dr
Page 353 and 354:
BNFC 2011-2012 5.4.1 Antimalarials
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
BNFC 2011-2012 5.4.2 Amoebicides 33
Page 363 and 364:
BNFC 2011-2012 5.4.6 Trypanocides 3
Page 365 and 366:
BNFC 2011-2012 5.4.8 Drugs for pneu
Page 367 and 368:
BNFC 2011-2012 5.5.2 Ascaricides 34
Page 369 and 370:
BNFC 2011-2012 5.5.8 Drugs for stro
Page 371 and 372:
BNFC 2011-2012 6.1.1 Insulins 349Tr
Page 373 and 374:
BNFC 2011-2012 6.1.1 Insulins 351So
Page 375 and 376:
BNFC 2011-2012 6.1.1 Insulins 353IN
Page 377 and 378:
BNFC 2011-2012 6.1.1 Insulins 355Hi
Page 379 and 380:
BNFC 2011-2012 6.1.2 Antidiabetic d
Page 381 and 382:
BNFC 2011-2012 6.1.2 Antidiabetic d
Page 383 and 384:
BNFC 2011-2012 6.1.4 Treatment of h
Page 385 and 386:
BNFC 2011-2012 6.1.6 Diagnostic and
Page 387 and 388:
BNFC 2011-2012 6.2 Thyroid and anti
Page 389 and 390:
BNFC 2011-2012 6.2.2 Antithyroid dr
Page 391 and 392:
Page 393 and 394:
BNFC 2011-2012 6.3.2 Glucocorticoid
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
BNFC 2011-2012 6.4 Sex hormones 377
Page 401 and 402:
BNFC 2011-2012 6.4.2 Male sex hormo
Page 403 and 404:
BNFC 2011-2012 6.4.3 Anabolic stero
Page 405 and 406:
BNFC 2011-2012 6.5.1 Hypothalamic a
Page 407 and 408:
BNFC 2011-2012 6.5.2 Posterior pitu
Page 409 and 410:
BNFC 2011-2012 6.5.2 Posterior pitu
Page 411 and 412:
BNFC 2011-2012 6.6.2 Bisphosphonate
Page 413 and 414:
BNFC 2011-2012 6.7.3 Metyrapone 391
Page 415 and 416:
BNFC 2011-2012 3937 Obstetrics, gyn
Page 417 and 418:
BNFC 2011-2012 7.2.2 Vaginal and vu
Page 419 and 420:
BNFC 2011-2012 7.3.1 Combined hormo
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
BNFC 2011-2012 7.3.2 Progestogen-on
Page 427 and 428:
BNFC 2011-2012 7.3.2 Progestogen-on
Page 429 and 430:
BNFC 2011-2012 7.3.4 Contraceptive
Page 431 and 432:
BNFC 2011-2012 7.4 Drugs for genito
Page 433 and 434:
BNFC 2011-2012 7.4.2 Drugs for urin
Page 435 and 436:
BNFC 2011-2012 7.4.5 Drugs for erec
Page 437 and 438:
BNFC 2011-2012 8.1 Cytotoxic drugs
Page 439 and 440:
BNFC 2011-2012 8.1 Cytotoxic drugs
Page 441 and 442:
BNFC 2011-2012 8.1.1 Alkylating dru
Page 443 and 444:
BNFC 2011-2012 8.1.2 Cytotoxic anti
Page 445 and 446:
BNFC 2011-2012 8.1.3 Antimetabolite
Page 447 and 448:
BNFC 2011-2012 8.1.3 Antimetabolite
Page 449 and 450:
BNFC 2011-2012 8.1.5 Other antineop
Page 451 and 452:
BNFC 2011-2012 8.1.5 Other antineop
Page 453 and 454:
BNFC 2011-2012 8.2 Drugs affecting
Page 455 and 456:
BNFC 2011-2012 8.2.2 Corticosteroid
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
BNFC 2011-2012 8.2.4 Other immunomo
Page 463 and 464:
BNFC 2011-2012 8.2.4 Other immunomo
Page 465 and 466:
BNFC 2011-2012 9.1.1 Iron-deficienc
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
BNFC 2011-2012 9.2.1 Oral preparati
Page 481 and 482:
BNFC 2011-2012 9.2.1 Oral preparati
Page 483 and 484:
BNFC 2011-2012 9.2.2 Parenteral pre
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
BNFC 2011-2012 9.3 Intravenous nutr
Page 491 and 492:
BNFC 2011-2012 9.4.2 Enteral nutrit
Page 493 and 494:
BNFC 2011-2012 9.5 Minerals 471dren
Page 495 and 496:
BNFC 2011-2012 9.5.1 Calcium and ma
Page 497 and 498:
BNFC 2011-2012 9.5.2 Phosphorus 475
Page 499 and 500:
BNFC 2011-2012 9.5.3 Fluoride 477Ch
Page 501 and 502:
BNFC 2011-2012 9.6.2 Vitamin B grou
Page 503 and 504:
BNFC 2011-2012 9.6.3 Vitamin C 481I
Page 505 and 506:
BNFC 2011-2012 9.6.4 Vitamin D 483N
Page 507 and 508:
BNFC 2011-2012 9.6.5 Vitamin E 4851
Page 509 and 510:
BNFC 2011-2012 9.6.7 Multivitamin p
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
BNFC 2011-2012 9.8.2 Acute porphyri
Page 521 and 522:
BNFC 2011-2012 49910 Musculoskeleta
Page 523 and 524:
BNFC 2011-2012 10.1.1 Non-steroidal
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
BNFC 2011-2012 10.1.3 Drugs that su
Page 531 and 532:
BNFC 2011-2012 10.1.3 Drugs that su
Page 533 and 534:
BNFC 2011-2012 10.1.4 Gout and cyto
Page 535 and 536:
BNFC 2011-2012 10.2.2 Skeletal musc
Page 537 and 538:
BNFC 2011-2012 10.2.2 Skeletal musc
Page 539 and 540:
BNFC 2011-2012 51711 Eye11.1 Admini
Page 541 and 542:
BNFC 2011-2012 11.3.1 Antibacterial
Page 543 and 544:
BNFC 2011-2012 11.3.3 Antivirals 52
Page 545 and 546:
BNFC 2011-2012 11.4.2 Other anti-in
Page 547 and 548:
BNFC 2011-2012 11.6 Treatment of gl
Page 549 and 550:
BNFC 2011-2012 11.6 Treatment of gl
Page 551 and 552:
BNFC 2011-2012 11.7 Local anaesthet
Page 553 and 554:
BNFC 2011-2012 11.8.1 Tear deficien
Page 555 and 556:
BNFC 2011-2012 11.9 Contact lenses
Page 557 and 558:
BNFC 2011-2012 12.1.1 Otitis extern
Page 559 and 560:
BNFC 2011-2012 12.1.2 Otitis media
Page 561 and 562:
Page 563 and 564:
BNFC 2011-2012 12.2.2 Topical nasal
Page 565 and 566:
BNFC 2011-2012 12.3 Drugs acting on
Page 567 and 568:
BNFC 2011-2012 12.3.2 Oropharyngeal
Page 569 and 570:
BNFC 2011-2012 12.3.4 Mouthwashes a
Page 571 and 572:
BNFC 2011-2012 12.3.5 Treatment of
Page 573 and 574:
BNFC 2011-2012 13.1.1 Vehicles 551m
Page 575 and 576:
BNFC 2011-2012 13.2.1 Emollients 55
Page 577 and 578:
BNFC 2011-2012 13.2.1 Emollients 55
Page 579 and 580:
BNFC 2011-2012 13.3 Topical antipru
Page 581 and 582:
BNFC 2011-2012 13.4 Topical cortico
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
BNFC 2011-2012 13.5 Preparations fo
Page 589 and 590:
BNFC 2011-2012 13.5.2 Preparations
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
BNFC 2011-2012 13.5.3 Drugs affecti
Page 597 and 598:
BNFC 2011-2012 13.6.1 Topical prepa
Page 599 and 600:
BNFC 2011-2012 13.6.1 Topical prepa
Page 601 and 602:
BNFC 2011-2012 13.6.2 Oral preparat
Page 603 and 604:
BNFC 2011-2012 13.7 Preparations fo
Page 605 and 606:
BNFC 2011-2012 13.8.2 Camouflagers
Page 607 and 608:
BNFC 2011-2012 13.10 Anti-infective
Page 609 and 610:
BNFC 2011-2012 13.10.1 Antibacteria
Page 611 and 612:
BNFC 2011-2012 13.10.2 Antifungal p
Page 613 and 614:
BNFC 2011-2012 13.10.3 Antiviral pr
Page 615 and 616:
Page 617 and 618:
BNFC 2011-2012 13.11.2 Chlorhexidin
Page 619 and 620:
BNFC 2011-2012 13.12 Antiperspirant
Page 621 and 622:
BNFC 2011-2012 59914 Immunological
Page 623 and 624:
BNFC 2011-2012 14.1 Active immunity
Page 625 and 626:
BNFC 2011-2012 14.4 Vaccines and an
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
BNFC 2011-2012 14.5.1 Normal Immuno
Page 647 and 648:
BNFC 2011-2012 14.5.2 Disease-speci
Page 649 and 650:
BNFC 2011-2012 14.6 International t
Page 651 and 652:
BNFC 2011-2012 15.1.1 Intravenous a
Page 653 and 654:
BNFC 2011-2012 15.1.1 Intravenous a
Page 655 and 656:
BNFC 2011-2012 15.1.2 Inhalational
Page 657 and 658:
BNFC 2011-2012 15.1.3 Antimuscarini
Page 659 and 660:
BNFC 2011-2012 15.1.4 Sedative and
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
BNFC 2011-2012 15.1.5 Neuromuscular
Page 667 and 668:
BNFC 2011-2012 15.1.5 Neuromuscular
Page 669 and 670:
BNFC 2011-2012 15.1.7 Antagonists f
Page 671 and 672:
BNFC 2011-2012 15.2 Local anaesthes
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
BNFC 2011-2012 655A1InteractionsTwo
Page 679 and 680:
BNFC 2011-2012 Appendix 1: Interact
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Page 733 and 734:
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747 and 748:
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
BNFC 2011-2012 743A2Borderline subs
Page 767 and 768:
Nutrison c(Nutricia Clinical)Nutris
Page 769 and 770:
A2.1.2 Enteral feeds (non-disease s
Page 771 and 772:
A2.1.2.2 Enteral feeds: Less than 1
Page 773 and 774: A2.1.3 Enteral feeds (non-disease s
Page 775 and 776: Infatrini c(Nutricia Clinical)Nutri
Page 777 and 778: Frebini c EnergyDrink(Fresenius Kab
Page 779 and 780: A2.2.1.2 Nutritional supplements: M
Page 781 and 782: Fortisip c Range(Nutricia Clinical)
Page 783 and 784: Forticreme cComplete(Nutricia Clini
Page 785 and 786: A2.3 Specialised formulasA2.3.1 Spe
Page 787 and 788: Nutramigen c Lipil 2(Mead Johnson)S
Page 789 and 790: Specialised formulas: Infant and ch
Page 791 and 792: KetoCal c(SHS)Standard dilution(20
Page 793 and 794: A2.4 Feed supplementsA2.4.1 High-en
Page 795 and 796: Medium-chainTriglyceride (MCT)Oil(S
Page 797 and 798: Calshake c(Fresenius Kabi)Powderper
Page 799 and 800: BNFC 2011-2012 A2.5 Feed additives
Page 801 and 802: BNFC 2011-2012 A2.6.1 Gluten-free f
Page 803 and 804: BNFC 2011-2012 A2.7 Nutritional sup
Page 811 and 812: BNFC 2011-2012 Appendix 3: Cautiona
Page 813 and 814: BNFC 2011-2012 791A4Intravenous inf
Page 815 and 816: BNFC 2011-2012 Appendix 4: Intraven
Page 817 and 818: BNFC 2011-2012 Dental Practitioners
Page 819 and 820: BNFC 2011-2012 Nurse Prescribers’
Page 821 and 822: BNFC 2011-2012 799Non-medical presc
Page 823: BNFC 2011-2012 Index of manufacture
Page 827 and 828: BNFC 2011-2012 Index of manufacture
Page 829 and 830: BNFC 2011-2012 Index of manufacture
Page 831 and 832: BNFC 2011-2012 809Special-orderManu
Page 833 and 834: BNFC 2011-2012 Abacavir—Alfacalci
Page 835 and 836: BNFC 2011-2012 Anthelios—Arthrofe
Page 837 and 838: BNFC 2011-2012 Benzodiazepines—Bu
Page 839 and 840: BNFC 2011-2012 Cetrimide—Cocaine
Page 841 and 842: BNFC 2011-2012 Coumarins—Dermatop
Page 843 and 844: BNFC 2011-2012 Disinfectants—Emer
Page 845 and 846: BNFC 2011-2012 Eye—Formaldehyde 8
Page 847 and 848: BNFC 2011-2012 Glycogen—Homatropi
Page 849 and 850: BNFC 2011-2012 Ibuprofen—Iodide 8
Page 851 and 852: BNFC 2011-2012 Laxatives—Magnesiu
Page 853 and 854: BNFC 2011-2012 Methylenedioxymetham
Page 855 and 856: BNFC 2011-2012 Nicardipine—Oftaqu
Page 857 and 858: BNFC 2011-2012 Paramax—Plaquenil
Page 859 and 860: BNFC 2011-2012 Procarbazine—Regul
Page 861 and 862: BNFC 2011-2012 Scottish—Sodium 83
Page 863 and 864: BNFC 2011-2012 Syringes—Tocophero
Page 865 and 866: BNFC 2011-2012 Ursofalk—Waxsol 84
Page 869 and 870: NEWBORN LIFE SUPPORTDry the babyRem
Page 871 and 872: PAEDIATRIC ADVANCED LIFE SUPPORTUnr
Page 873 and 874: BODY SURFACE AREA IN CHILDRENBody-w
Page 875 and 876:
Croup(section 3.1)Dexamethasone ora
Page 877 and 878:
Recommended wording of cautionaryan
show all

BNF for Children 2011-2012

Create successful ePaper yourself

Delete template?

Save as template?